Charles River Laboratories International (NYSE:CRL) Downgraded to Market Perform Rating by William Blair

William Blair downgraded shares of Charles River Laboratories International (NYSE:CRL) from an outperform rating to a market perform rating in a research report report published on Wednesday morning, MarketBeat Ratings reports. William Blair also issued estimates for Charles River Laboratories International’s FY2025 earnings at $9.40 EPS.

A number of other brokerages also recently weighed in on CRL. Redburn Atlantic assumed coverage on shares of Charles River Laboratories International in a research report on Monday, October 14th. They set a “sell” rating and a $151.00 price objective on the stock. Bank of America reduced their target price on shares of Charles River Laboratories International from $220.00 to $210.00 and set a “neutral” rating for the company in a report on Friday, December 13th. CLSA cut shares of Charles River Laboratories International from a “hold” rating to an “underperform” rating and set a $164.00 target price for the company. in a report on Monday, November 18th. UBS Group reaffirmed a “neutral” rating and set a $185.00 target price (down from $250.00) on shares of Charles River Laboratories International in a report on Friday, January 17th. Finally, StockNews.com cut shares of Charles River Laboratories International from a “buy” rating to a “hold” rating in a report on Thursday, November 7th. Three analysts have rated the stock with a sell rating, thirteen have issued a hold rating and one has issued a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $209.00.

Charles River Laboratories International Stock Down 0.9 %

Shares of Charles River Laboratories International stock opened at $168.27 on Wednesday. The company has a market cap of $8.61 billion, a price-to-earnings ratio of 21.06, a price-to-earnings-growth ratio of 5.75 and a beta of 1.38. The company’s 50 day moving average is $187.81 and its 200 day moving average is $197.72. Charles River Laboratories International has a twelve month low of $160.85 and a twelve month high of $275.00. The company has a quick ratio of 1.14, a current ratio of 1.48 and a debt-to-equity ratio of 0.61.

Charles River Laboratories International (NYSE:CRL) last issued its quarterly earnings data on Wednesday, November 6th. The medical research company reported $2.59 earnings per share for the quarter, beating analysts’ consensus estimates of $2.43 by $0.16. The company had revenue of $1.01 billion for the quarter, compared to the consensus estimate of $975.99 million. Charles River Laboratories International had a net margin of 10.44% and a return on equity of 14.29%. The firm’s revenue for the quarter was down 1.6% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $2.72 earnings per share. Research analysts anticipate that Charles River Laboratories International will post 10.18 EPS for the current year.

Insider Activity at Charles River Laboratories International

In other Charles River Laboratories International news, Director Richard F. Wallman sold 6,621 shares of the stock in a transaction on Thursday, November 7th. The shares were sold at an average price of $216.12, for a total transaction of $1,430,930.52. Following the completion of the transaction, the director now owns 12,386 shares in the company, valued at $2,676,862.32. This trade represents a 34.83 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 1.30% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Charles River Laboratories International

Several institutional investors have recently bought and sold shares of CRL. Versant Capital Management Inc lifted its position in Charles River Laboratories International by 1,071.4% during the fourth quarter. Versant Capital Management Inc now owns 164 shares of the medical research company’s stock valued at $30,000 after purchasing an additional 150 shares during the last quarter. Wolff Wiese Magana LLC bought a new position in Charles River Laboratories International during the third quarter valued at $32,000. Pinnacle Bancorp Inc. lifted its position in Charles River Laboratories International by 52.0% during the fourth quarter. Pinnacle Bancorp Inc. now owns 190 shares of the medical research company’s stock valued at $35,000 after purchasing an additional 65 shares during the last quarter. Assetmark Inc. lifted its position in Charles River Laboratories International by 1,153.3% during the third quarter. Assetmark Inc. now owns 188 shares of the medical research company’s stock valued at $37,000 after purchasing an additional 173 shares during the last quarter. Finally, ORG Wealth Partners LLC bought a new stake in shares of Charles River Laboratories International in the 4th quarter worth about $56,000. Institutional investors own 98.91% of the company’s stock.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).